Genmab A/S (NASDAQ:GMAB) Downgraded to “Hold” Rating by Wall Street Zen

Genmab A/S (NASDAQ:GMAB) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Saturday.

Several other research analysts have also issued reports on GMAB. HC Wainwright reissued a “buy” rating and issued a $39.00 price target on shares of Genmab A/S in a research report on Wednesday, January 28th. Zacks Research cut Genmab A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, October 31st. Truist Financial restated a “buy” rating and set a $48.00 target price (down previously from $49.00) on shares of Genmab A/S in a research report on Thursday, November 6th. Finally, Johnson Rice reiterated a “buy” rating on shares of Genmab A/S in a research report on Monday, October 27th. Six research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Genmab A/S presently has an average rating of “Moderate Buy” and an average target price of $39.25.

Genmab A/S Price Performance

Shares of GMAB stock opened at $30.90 on Friday. Genmab A/S has a one year low of $17.24 and a one year high of $35.43. The stock has a fifty day moving average price of $32.50 and a 200 day moving average price of $29.41. The stock has a market cap of $19.85 billion, a P/E ratio of 13.15, a price-to-earnings-growth ratio of 18.18 and a beta of 0.90.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.17. Genmab A/S had a net margin of 41.36% and a return on equity of 23.98%. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $975.40 million. Equities research analysts anticipate that Genmab A/S will post 1.45 EPS for the current year.

Hedge Funds Weigh In On Genmab A/S

Institutional investors and hedge funds have recently bought and sold shares of the business. Federated Hermes Inc. acquired a new stake in Genmab A/S during the 3rd quarter worth $12,972,000. JPMorgan Chase & Co. grew its stake in shares of Genmab A/S by 17.0% during the second quarter. JPMorgan Chase & Co. now owns 933,309 shares of the company’s stock worth $19,282,000 after purchasing an additional 135,814 shares during the period. Squarepoint Ops LLC increased its holdings in Genmab A/S by 636.3% in the second quarter. Squarepoint Ops LLC now owns 94,233 shares of the company’s stock valued at $1,947,000 after purchasing an additional 81,434 shares during the last quarter. Eagle Global Advisors LLC lifted its stake in Genmab A/S by 16.3% in the third quarter. Eagle Global Advisors LLC now owns 244,470 shares of the company’s stock valued at $7,498,000 after buying an additional 34,175 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in Genmab A/S by 152.3% during the second quarter. Arrowstreet Capital Limited Partnership now owns 3,454,378 shares of the company’s stock worth $71,367,000 after buying an additional 2,084,966 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.